Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2022-11-10 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
第四届监事会第十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the convening and decisions made during the 13th meeting of the 4th Supervisory Board, including approvals related to the use of idle raised funds, appointment of an accounting firm, and other supervisory matters. The document includes voting results and references to related announcements but does not contain financial statements or detailed financial data. It is a formal meeting resolution announcement rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and meeting resolutions that do not fit other specific categories.
2022-11-10 Chinese
关于使用部分闲置募集资金用于暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of part of its idle raised funds to temporarily supplement working capital. It details the approval by the board and supervisory committee, references regulatory compliance with Shenzhen Stock Exchange rules, and provides specifics on the amount and duration of the fund usage. The document does not contain financial statements or detailed financial performance data but is a formal disclosure about the company's capital usage plans. The length is about 4,314 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Capital/Financing Update (CAP) since it concerns the use of raised funds and capital management.
2022-11-10 Chinese
中天国富证券有限公司关于新乡拓新药业股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsoring securities company (中天国富证券有限公司) regarding the use of idle raised funds by 新乡拓新药业股份有限公司 for cash management. It includes specifics about the raised funds, investment projects, board and supervisory approvals, independent director opinions, risk analysis, and compliance with regulatory requirements. The document is not a brief announcement but a substantive report on the use and management of raised funds, including financial figures and governance procedures. It is not an annual or interim report, nor an earnings release or a simple announcement. It is a regulatory compliance and audit-related report focusing on the use of raised funds and their management, which fits the category of Audit Report / Information (AR). The document length is 4308 characters, which is substantive enough to be a report rather than a mere announcement. Therefore, the best classification is AR (Audit Report / Information). FY 2022
2022-11-10 Chinese
第四届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 18th meeting of the 4th Board of Directors of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, and the voting results on various proposals such as the use of idle raised funds, appointment of an audit firm, and scheduling of a shareholders' meeting. The content focuses on board decisions and governance matters rather than financial results or detailed reports. It is not a full annual or interim report, audit report, or earnings release. It is not a call transcript or investor presentation. The document is a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is 2313 characters, which is consistent with a meeting resolution announcement rather than a full report.
2022-11-10 Chinese
关于召开2022年第六次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2022 sixth extraordinary general meeting (临时股东大会) of shareholders for a company, including information on meeting date, voting procedures (both onsite and online), registration details, agenda items, and proxy forms. It does not contain financial statements, audit results, or management discussion of financial performance. It is not a report but a formal announcement and invitation to shareholders to attend and vote at the meeting. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-11-10 Chinese
关于持股5%以上股东部分股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from a company regarding the release of a partial pledge of shares by a shareholder holding more than 5% of the company's shares. It details the number of shares released from pledge, the shareholder involved, and the status of pledged shares. There is no financial report, earnings data, or management discussion. The document is a notification about share pledge status changes by a significant shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or announcement of a meeting or dividend.
2022-11-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.